MedTrace Logo

A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo

NCT05053022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo. Vitiligo is an autoimmune depigmentation disease of the skin that is characterized by the destruction of epidermal melanocytes by CD8+ T cells. The pathogenesis of Vitiligo has been linked to autoimmunity, oxidative stress, and genetic susceptibility.

Conditions

  • Vitiligo

Interventions

DEVICE

Skinpen Precision System

Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.

Sponsors & Collaborators

  • Crown Laboratories, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-29
Primary Completion
2022-11-21
Completion
2023-01-24
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053022 on ClinicalTrials.gov